Monopar Therapeutics Inc. Operating Cash Flow
Monopar Therapeutics Inc. (MNPR) reported Operating Cash Flow of -$6.72 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- Monopar Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$3.25M.
- Monopar Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$3.47M.
- Monopar Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$3.37M.
- Monopar Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$2.09M.
- Monopar Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$12.20M.
- Monopar Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$6.40M.
- Monopar Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$7.86M.
- Monopar Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$7.23M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$3.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$6.72M 10-Q · filed 2026-08-12 | -$10.09M derived: sum of 3 quarters · filed 2026-08-12 | -$12.18M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | -$3.47M 10-Q · filed 2026-05-14 | -$6.84M derived: sum of 2 quarters · filed 2026-05-14 | -$8.93M derived: sum of 3 quarters · filed 2026-05-14 | -$10.01M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | -$3.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$5.46M derived: sum of 2 quarters · filed 2026-03-27 | -$6.54M derived: sum of 3 quarters · filed 2026-08-12 | -$12.20M 10-K · filed 2026-03-27 | |
| 2025-09-30 | -$2.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$3.17M derived: sum of 2 quarters · filed 2026-08-12 | -$8.83M 10-Q · filed 2025-11-13 | -$10.83M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | -$1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$6.74M 10-Q · filed 2026-08-12 | -$8.74M derived: sum of 3 quarters · filed 2026-08-12 | -$9.81M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | -$5.66M 10-Q · filed 2026-05-14 | -$7.66M derived: sum of 2 quarters · filed 2026-05-14 | -$8.74M derived: sum of 3 quarters · filed 2026-05-14 | -$10.41M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$3.07M derived: sum of 2 quarters · filed 2026-03-27 | -$4.75M derived: sum of 3 quarters · filed 2026-03-27 | -$6.40M 10-K · filed 2026-03-27 | |
| 2024-09-30 | -$1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$2.75M derived: sum of 2 quarters · filed 2025-11-13 | -$4.41M 10-Q · filed 2025-11-13 | -$5.95M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | -$1.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$3.33M 10-Q · filed 2025-08-12 | -$4.88M derived: sum of 3 quarters · filed 2025-08-12 | -$6.82M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$1.66M 10-Q · filed 2025-05-13 | -$3.20M derived: sum of 2 quarters · filed 2025-05-13 | -$5.14M derived: sum of 3 quarters · filed 2025-05-13 | -$7.24M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | -$1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$3.49M derived: sum of 2 quarters · filed 2025-03-31 | -$5.59M derived: sum of 3 quarters · filed 2025-03-31 | -$7.86M 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$4.04M derived: sum of 2 quarters · filed 2024-11-08 | -$6.31M 10-Q · filed 2024-11-08 | -$7.61M derived: sum of 4 quarters · filed 2024-11-08 | |
| 2023-06-30 | -$2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$4.37M 10-Q · filed 2024-08-09 | -$5.67M derived: sum of 3 quarters · filed 2024-08-09 | -$7.82M derived: sum of 4 quarters · filed 2024-08-09 | |
| 2023-03-31 | -$2.27M 10-Q · filed 2024-05-09 | -$3.57M derived: sum of 2 quarters · filed 2024-05-09 | -$5.72M derived: sum of 3 quarters · filed 2024-05-09 | -$7.03M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | -$1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$3.45M derived: sum of 2 quarters · filed 2024-03-28 | -$4.76M derived: sum of 3 quarters · filed 2024-03-28 | -$7.23M 10-K · filed 2024-03-28 | |
| 2022-09-30 | -$2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$3.46M derived: sum of 2 quarters · filed 2023-11-09 | -$5.93M 10-Q · filed 2023-11-09 | -$7.96M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | -$1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$3.78M 10-Q · filed 2023-08-10 | -$5.81M derived: sum of 3 quarters · filed 2023-08-10 | -$7.75M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | -$2.47M 10-Q · filed 2023-05-11 | -$4.50M derived: sum of 2 quarters · filed 2023-05-11 | -$6.44M derived: sum of 3 quarters · filed 2023-05-11 | -$7.85M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$3.97M derived: sum of 2 quarters · filed 2023-03-23 | -$5.38M derived: sum of 3 quarters · filed 2023-03-23 | -$7.32M 10-K · filed 2023-03-23 | $7.32M 10-K · filed 2022-03-24 |
| 2021-09-30 | -$1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$3.35M derived: sum of 2 quarters · filed 2022-11-10 | -$5.29M 10-Q · filed 2022-11-10 | -$6.53M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$1.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$3.34M 10-Q · filed 2022-08-11 | -$4.58M derived: sum of 3 quarters · filed 2022-08-11 | -$5.89M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$1.94M 10-Q · filed 2022-05-12 | -$3.18M derived: sum of 2 quarters · filed 2022-05-12 | -$4.48M derived: sum of 3 quarters · filed 2022-05-12 | -$5.47M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | -$2.54M derived: sum of 2 quarters · filed 2022-03-24 | -$3.54M derived: sum of 3 quarters · filed 2022-03-24 | -$4.66M 10-K · filed 2022-03-24 | |
| 2020-09-30 | -$1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$2.30M derived: sum of 2 quarters · filed 2021-11-12 | -$3.42M 10-Q · filed 2021-11-12 | -$4.09M derived: sum of 4 quarters · filed 2021-11-12 | |
| 2020-06-30 | -$995.47K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$2.12M 10-Q · filed 2021-08-12 | -$2.79M derived: sum of 3 quarters · filed 2021-08-12 | -$3.40M derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | -$1.13M 10-Q · filed 2021-05-13 | -$1.79M derived: sum of 2 quarters · filed 2021-05-13 | -$2.41M derived: sum of 3 quarters · filed 2021-05-13 | -$3.15M derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | -$668.71K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$1.28M derived: sum of 2 quarters · filed 2021-03-25 | -$2.02M derived: sum of 3 quarters · filed 2021-03-25 | -$3.02M 10-K · filed 2021-03-25 | |
| 2019-09-30 | -$613.27K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$1.35M derived: sum of 2 quarters · filed 2020-11-12 | -$2.35M 10-Q · filed 2020-11-12 | -$2.87M derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | -$739.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$1.74M 10-Q · filed 2020-08-06 | -$2.25M derived: sum of 3 quarters · filed 2020-08-06 | -$2.85M derived: sum of 4 quarters · filed 2020-08-06 | |
| 2019-03-31 | -$995.97K 10-Q · filed 2020-05-07 | -$1.52M derived: sum of 2 quarters · filed 2020-05-07 | -$2.11M derived: sum of 3 quarters · filed 2020-05-07 | -$2.87M derived: sum of 4 quarters · filed 2020-05-07 | |
| 2018-12-31 | -$519.21K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | -$1.12M derived: sum of 2 quarters · filed 2020-03-27 | -$1.87M derived: sum of 3 quarters · filed 2020-03-27 | -$2.68M 10-K · filed 2020-03-27 | -$2.89M 10-K · filed 2019-02-26 |
| 2018-09-30 | -$599.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$1.35M derived: sum of 2 quarters · filed 2019-11-12 | -$2.16M 10-Q · filed 2019-11-12 | -$2.98M derived: sum of 4 quarters · filed 2019-11-12 | |
| 2018-06-30 | -$752.86K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$1.56M 10-Q · filed 2019-08-08 | -$2.38M derived: sum of 3 quarters · filed 2019-08-08 | -$3.57M derived: sum of 4 quarters · filed 2019-08-08 | |
| 2018-03-31 | -$808.85K 10-Q · filed 2019-05-10 | -$1.62M derived: sum of 2 quarters · filed 2019-05-10 | -$2.82M derived: sum of 3 quarters · filed 2019-05-10 | -$3.12M derived: sum of 4 quarters · filed 2019-05-10 | |
| 2017-12-31 | -$816.02K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$2.01M derived: sum of 2 quarters · filed 2019-02-26 | -$2.32M derived: sum of 3 quarters · filed 2019-02-26 | -$2.63M 10-K · filed 2019-02-26 | |
| 2017-09-30 | -$1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$1.50M derived: sum of 2 quarters · filed 2018-11-09 | -$1.81M 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | -$305.13K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$616.61K 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | -$311.49K 10-Q · filed 2018-05-11 | ||||
| 2016-12-31 | -$1.19M 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |